[Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans].

Abstract

A 37-year-old man was diagnosed with metastatic dermatofibrosarcoma. Dermatofibrosarcoma protuberans is a rare skin tumour with a strong tendency for infiltrative growth, resulting in a high rate of local recurrences; metastatic disease develops in approximately 5% of patients, especially in the lungs. On the basis of some recent publications about the use of imatinib in patients with dermatofibrosarcoma, the patient was prescribed this drug. The treatment resulted in a partial response. Imatinib is the first registered selective tyrosine-kinase inhibitor for treatment of chronic myeloid leukaemia. The inhibition of tyrosine kinase interrupts the proliferative signal transduction.

• Authors: A Baars, H M Pinedo
• Journal: Nederlands tijdschrift voor geneeskunde (Ned Tijdschr Geneeskd) Vol. 147 Issue 42 Pg. 2072-6 (Oct 18 2003) ISSN: 0028-2162 [Print] Netherlands
• Vernacular Title: Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een patiënt met gemetastaseerd dermatofibrosarcoma protuberans.
• PMID: 14606355 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Benzamides
• Enzyme Inhibitors
• Piperazines
• Pyrimidines
• Imatinib Mesylate
• Protein-Tyrosine Kinases

Topics

• Adult
• Benzamides
• Dermatofibrosarcoma (drug therapy, secondary)
• Enzyme Inhibitors (therapeutic use)
• Humans
• Imatinib Mesylate
• Male
• Neoplasm Recurrence, Local (prevention & control)
• Piperazines (therapeutic use)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Pyrimidines (therapeutic use)
• Skin Neoplasms (drug therapy, pathology)
• Treatment Outcome